Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.
Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine. |
| Hydrocodone | Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine. |
| Magnesium sulfate | The therapeutic efficacy of Pipotiazine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine. |
| Mirtazapine | Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine. |
| Orphenadrine | Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine. |
| Rotigotine | Pipotiazine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Pipotiazine. |
| Sodium oxybate | The risk or severity of CNS depression can be increased when Pipotiazine is combined with Sodium oxybate. |
| Suvorexant | Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine. |
| Thalidomide | Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Pipotiazine may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Pipotiazine. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Pipotiazine. |
| Sulpiride | Pipotiazine may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Pipotiazine. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Pipotiazine. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Pipotiazine. |
| Mequitazine | Pipotiazine may increase the arrhythmogenic activities of Mequitazine. |
| Thiopental | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Thiopental. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Pipotiazine. |
| Metyrosine | The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with Pipotiazine. |
| Mirabegron | The serum concentration of Pipotiazine can be increased when it is combined with Mirabegron. |
| Ethanol | Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine. |
| Citalopram | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Citalopram. |
| Trazodone | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Trazodone. |
| Sertraline | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Sibutramine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Milnacipran. |
| Desvenlafaxine | The serum concentration of Pipotiazine can be increased when it is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Pipotiazine. |
| Indalpine | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Indalpine. |
| Alaproclate | The risk or severity of adverse effects can be increased when Pipotiazine is combined with Alaproclate. |
| Esmolol | The serum concentration of Esmolol can be increased when it is combined with Pipotiazine. |
| Betaxolol | The serum concentration of Betaxolol can be increased when it is combined with Pipotiazine. |
| Atenolol | The serum concentration of Atenolol can be increased when it is combined with Pipotiazine. |
| Propranolol | The serum concentration of Propranolol can be increased when it is combined with Pipotiazine. |
| Labetalol | The serum concentration of Labetalol can be increased when it is combined with Pipotiazine. |
| Bisoprolol | The serum concentration of Bisoprolol can be increased when it is combined with Pipotiazine. |
| Alprenolol | The serum concentration of Alprenolol can be increased when it is combined with Pipotiazine. |
| Pindolol | The serum concentration of Pindolol can be increased when it is combined with Pipotiazine. |
| Carvedilol | The serum concentration of Carvedilol can be increased when it is combined with Pipotiazine. |
| Acebutolol | The serum concentration of Acebutolol can be increased when it is combined with Pipotiazine. |
| Nadolol | The serum concentration of Nadolol can be increased when it is combined with Pipotiazine. |
| Bevantolol | The serum concentration of Bevantolol can be increased when it is combined with Pipotiazine. |
| Practolol | The serum concentration of Practolol can be increased when it is combined with Pipotiazine. |
| Penbutolol | The serum concentration of Penbutolol can be increased when it is combined with Pipotiazine. |
| Oxprenolol | The serum concentration of Oxprenolol can be increased when it is combined with Pipotiazine. |
| Dexpropranolol | The serum concentration of Dexpropranolol can be increased when it is combined with Pipotiazine. |
| Celiprolol | The serum concentration of Celiprolol can be increased when it is combined with Pipotiazine. |
| Nebivolol | The serum concentration of Nebivolol can be increased when it is combined with Pipotiazine. |
| Bufuralol | The serum concentration of Bufuralol can be increased when it is combined with Pipotiazine. |
| Bopindolol | The serum concentration of Bopindolol can be increased when it is combined with Pipotiazine. |
| Bupranolol | The serum concentration of Bupranolol can be increased when it is combined with Pipotiazine. |
| Indenolol | The serum concentration of Indenolol can be increased when it is combined with Pipotiazine. |
| Arotinolol | The serum concentration of Arotinolol can be increased when it is combined with Pipotiazine. |
| Levobetaxolol | The serum concentration of Levobetaxolol can be increased when it is combined with Pipotiazine. |
| Talinolol | The serum concentration of Talinolol can be increased when it is combined with Pipotiazine. |
| Anisodamine | The serum concentration of Anisodamine can be increased when it is combined with Pipotiazine. |
| Bucindolol | The serum concentration of Bucindolol can be increased when it is combined with Pipotiazine. |
| Esatenolol | The serum concentration of Esatenolol can be increased when it is combined with Pipotiazine. |
| Cloranolol | The serum concentration of Cloranolol can be increased when it is combined with Pipotiazine. |
| Mepindolol | The serum concentration of Mepindolol can be increased when it is combined with Pipotiazine. |
| Epanolol | The serum concentration of Epanolol can be increased when it is combined with Pipotiazine. |
| Tertatolol | The serum concentration of Tertatolol can be increased when it is combined with Pipotiazine. |
| Morphine | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Morphine. |
| Codeine | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Codeine. |
| Hydromorphone | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Hydromorphone. |
| Oxycodone | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Oxycodone. |
| Butorphanol | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Pentazocine. |
| Naltrexone | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Naltrexone. |
| Sufentanil | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Sufentanil. |
| Nalbuphine | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Nalbuphine. |
| Levorphanol | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Levorphanol. |
| Remifentanil | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Oxymorphone. |
| Dezocine | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Dezocine. |
| Methadyl acetate | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Diamorphine. |